This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Comment: Illumina-PacBio get sliver of hope in persuading UK merger probe they aren’t rivals

By Victoria Ibitoye and Nicholas Hirst ( August 2, 2019, 13:09 GMT | Comment) -- While would-be merger partners Illumina and Pacific Biosciences appear to be direct competitors, it's possible their services address different needs, UK competition investigators have said. That caveat offers a small ray of hope to the DNA sequencers' deal, even as it sets the scene for a bruising fight over market definition in the UK regulator's probe.Illumina and Pacific Biosciences have been offered a small ray of hope for their would-be merger by UK antitrust investigators, who say the DNA sequencers may not be the direct competitors they seem....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login